Výsledky vyhledávání - "D. H. Schwartz"

Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines

Autor: S H Pincus, K G Messer, R Cole, R Ireland, T C VanCott, A Pinter, D H Schwartz, B S Graham, G J Gorse

Publikováno v: The Journal of Immunology. 158:3511-3520

The first generation of candidate vaccines to prevent HIV infection consisted of recombinant envelope proteins (Env, gp120, and gp160) derived from a single laboratory strain of HIV, designated IIIB/LAV, but produced with different expression systems

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04313bbd06711a7259a388c1a659bcea
https://doi.org/10.4049/jimmunol.158.7.3511

Zobrazit plný text záznamu

V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network

Autor: D C Montefiori, B S Graham, J Zhou, R A Bucco, D H Schwartz, L A Cavacini, M R Posner

Publikováno v: Journal of Clinical Investigation. 92:840-847

Sera from 11 volunteers immunized with a recombinant HIV-1 gp160-expressing vaccinia virus (HIVAC-1e; Oncogen/Bristol-Myers Squibb, Seattle, WA) and boosted with baculovirus-derived rgp160 (VaxSyn; MicroGeneSys, Inc., Meriden, CT) were evaluated for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a850e63fa94b70cd4e2825685d07b2df
https://doi.org/10.1172/jci116658

Zobrazit plný text záznamu

T cell-tropic HIV gp120 mediates CD4 and CD8 cell chemotaxis through CXCR4 independent of CD4: implications for HIV pathogenesis

Autor: S, Iyengar, D H, Schwartz, J E, Hildreth

Publikováno v: Journal of immunology (Baltimore, Md. : 1950). 162(10)

HIV entry is determined by one or more chemokine receptors. T cell-tropic viruses bind CXCR4, whereas macrophage-tropic viruses use CCR5 and other CCRs. Infection with CXCR4 and CCR5-tropic HIV requires initial binding to CD4, and chemotaxis induced

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::718747618f335716aff8ae1e174ce5b9
https://pubmed.ncbi.nlm.nih.gov/10229873

Zobrazit plný text záznamu

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3

Autor: D P, Francis, T, Gregory, M J, McElrath, R B, Belshe, G J, Gorse, S, Migasena, D, Kitayaporn, P, Pitisuttitham, T, Matthews, D H, Schwartz, P W, Berman

Publikováno v: AIDS research and human retroviruses. 14

AIDSVAX (VaxGen, Inc., South San Francisco, CA), a possible vaccine to protect against human immunodeficiency virus type 1 (HIV-1) infection, is being tested for efficacy in phase 3 studies. It has been tested for potential efficacy in chimpanzees, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bb60ac11d22eadc9b6ca4b1be0f342c0
https://pubmed.ncbi.nlm.nih.gov/9814961

Zobrazit plný text záznamu

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group

Autor: B S, Graham, M J, McElrath, R I, Connor, D H, Schwartz, G J, Gorse, M C, Keefer, M J, Mulligan, T J, Matthews, S M, Wolinsky, D C, Montefiori, S H, Vermund, J S, Lambert, L, Corey, R B, Belshe, R, Dolin, P F, Wright, B T, Korber, M C, Wolff, P E, Fast

Publikováno v: The Journal of infectious diseases. 177(2)

Among 2099 uninfected subjects in phase I and II trials of candidate AIDS vaccines, 23 were diagnosed with intercurrent human immunodeficiency virus type 1 (HIV-1) infection. High-risk sexual exposures accounted for 17 infections, and intravenous dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3eae35717f1a9d7e47373b99281b3523
https://pubmed.ncbi.nlm.nih.gov/9466516

Zobrazit plný text záznamu

Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines

Autor: S H, Pincus, K G, Messer, R, Cole, R, Ireland, T C, VanCott, A, Pinter, D H, Schwartz, B S, Graham, G J, Gorse

Publikováno v: Journal of immunology (Baltimore, Md. : 1950). 158(7)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6ee81a7113694c3e441da7211f5fba53
https://pubmed.ncbi.nlm.nih.gov/9120313

Zobrazit plný text záznamu

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

Autor: B S, Graham, M C, Keefer, M J, McElrath, G J, Gorse, D H, Schwartz, K, Weinhold, T J, Matthews, J R, Esterlitz, F, Sinangil, P E, Fast

Publikováno v: Annals of internal medicine. 125(4)

To evaluate the safety and immunogenicity of recombinant glycoprotein (rgp) 120, a candidate vaccine for the human immunodeficiency virus (HIV), formulated with a novel adjuvant, MF59, with or without a biological response modifier, MTP-PE.Multicente

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d96ceb875e4bdd7427321524b9a4daa4
https://pubmed.ncbi.nlm.nih.gov/8678389

Zobrazit plný text záznamu

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

Autor: J R, Mascola, S W, Snyder, O S, Weislow, S M, Belay, R B, Belshe, D H, Schwartz, M L, Clements, R, Dolin, B S, Graham, G J, Gorse, M C, Keefer, M J, McElrath, M C, Walker, K F, Wagner, J G, McNeil, F E, McCutchan, D S, Burke

Publikováno v: The Journal of infectious diseases. 173(2)

Phase I studies of volunteers not infected with human immunodeficiency virus type 1 (HIV-1) have shown that immunization with envelope subunit vaccine products elicits antibodies that neutralize laboratory-adapted (prototype) HIV-1 strains in vitro.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b66cb4aed46df8c655ec02ef12440b28
https://pubmed.ncbi.nlm.nih.gov/8568294

Zobrazit plný text záznamu

A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees

Autor: M A, Perales, D H, Schwartz, J A, Fabry, J, Lieberman

Publikováno v: Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association. 10(1)

Cytotoxic T lymphocytes (CTL) play an important role in the immune response to viral infection by recognizing and destroying infected cells. HIV-1 elicits an unusually strong CTL response in infected individuals and clearance of the viremia of acute

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7db82654c8ad10e8fb98c55a1520c2bd
https://pubmed.ncbi.nlm.nih.gov/7648281

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání